$3.07
-4.1%SBC Medical Group Holdings Incorporated provides management services to cosmetic treatment centers in Japan, Vietnam, the United States, and internationally. The company offers advertising and marketing services; staff management services, such as recruitment and training; booking reservations for franchisee clinic customers; assistance with franchisee employee housing rentals and facility rentals; construction and design of franchisee clinics; medical equipment; and medical consumables procurement. It provides IT software solutions; breast augmentation, liposuction, and rejuvenation treatments, including treatment of wrinkles, acne, scars, cellulite, excess fat, discoloration, and signs of aging; laser skin toning and spot removal; eyes double fold surgery; rhinoplasty; treatment of osmidrosis and hyperhidrosis; hair transplants; gynecological formation treatments; laser hair removal; face line surgeries; cosmetical dental procedures; tattoo removal; lasik eye surgery; lateral canthoplasty; brow lift procedures; androgenetic alopecia treatment; and cheek sagging prevention methods. The company was founded in 2000 and is headquartered in Irvine, California.
Chairman & Chief Executive Officer
Compensation
$14,506,032
Chief Operating Officer, Chief Financial Officer & Director
Compensation
$304,404
Chief Strategy Officer
Marketing Director
Compensation
$193,496
Principal Accounting Officer
Compensation
$136,990
Property Acquisition Director
Compensation
$103,740
Secretary
Compensation
$77,189
During the last 12 months, insiders have sold $20.15M worth of SBC shares, with no buying activity reported.
0
0.00
8.0M
20.15M
-20.2M
-$20.15M
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
No buying activity
Aikawa Yoshiyuki
Director, 10 Percent Owner, Officer: Chairman And Ceo
$20.15M
Strong bearish signal with $20.15M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
1 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Persistent selling pressure: Consistent insider selling with weak buy/sell ratio suggests insiders may be capitalizing on current valuation. Exercise caution and review recent earnings quality and management commentary.
SBC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | May 28, 2026 | May 28, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | May 28, 2025 | May 28, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | January 23, 2024 | January 23, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 24, 2023 | April 24, 2023 | 2023 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.